Clinical TrialsSearch results
Number of results: 562
Other
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- Early Breast Cancer
- Tanja Badovinac Crnjevic
- 2021-10-02
Recruiting
- A Phase 3 trial of BAY 2927088 compared with standard of care as first-line therapy for advanced non-small cell lung cancer (NSCLC) with HER2 mutations
- Advanced non-small cell lung cancer
- Tanigawa Takahiko
- 2024-08-01
Other
- Regorafenib rollover study
- Solid Tumors
- Tanigawa Takahiko
- 2024-01-26
Recruiting
- Substudy 06B: Phase 1/2 Umbrella Study of Investigational Agents With or Without Pembrolizumab and/or Chemotherapy in Esophageal Cancer
- Esophageal Squamous Cell Carcinoma (ESCC)
- Tanaka Yoshiyuki
- 2023-01-22
Recruiting
- MK-3475 Monotherapy versus Sacituzumab Govitecan in Combination with MK-3475 for PD-L1 TPS >=50% Metastatic NSCLC
- NSCLC
- Tanaka Yoshiyuki
- 2023-04-16
Recruiting
- MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer
- Endometrial cancer
- Tanaka Yoshiyuki
- 2024-04-21
Other
- Substudy 06A: Phase 1/2 Umbrella Study of Combination Therapies in Esophageal Cancer
- Esophageal Squamous Cell Carcinoma (ESCC)
- Tanaka Yoshiyuki
- 2022-07-08
Other
- Phase 2b Study of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis
- Nonalcoholic Steatohepatitis
- Tanaka Yoshiyuki
- 2023-06-28
Other
- MK-3475A SC vs pembrolizumab IV, administered with chemotherapy, in treatment-naive metastatic NSCLC
- Metastatic Non-small Cell Lung Cancer
- Tanaka Yoshiyuki
- 2023-04-22
Other
- An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced ccRCC
- Renal cell carcinoma
- Tanaka Yoshiyuki
- 2021-11-19